Related Experiment Video
Updated: Aug 17, 2026
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
State-of-the art therapy for gastrointestinal stromal tumors
Charles D Blanke1, Christopher L Corless
1Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97201, USA. blankec@ohsu.edu
Abstract:
Until recently, there were few effective therapeutic options for patients with gastrointestinal stromal tumors (GISTs). Most patients undergoing even potentially curative resection for early-stage disease recurred if followed for a sufficiently long period, and treatment of advanced tumors with systemic chemotherapy was ineffective. Imatinib mesylate, a molecularly targeted agent that inhibits the KIT receptor tyrosine kinase, has now been demonstrated to be highly effective at inducing objective responses in GIST patients, and it improves overall survival. In locoregional disease, ongoing studies are assessing the use of imatinib pre-or postsurgery. In addition, other agents possessing activity against a variety of molecular targets are being tested in advanced disease. Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance.
Insights
Imatinib mesylate offers a breakthrough therapy for gastrointestinal stromal tumors (GISTs), significantly improving patient responses and survival rates where chemotherapy previously failed. Ongoing research explores optimal imatinib use and resistance mechanisms.
Area of Science:
- Oncology
- Molecular Targeted Therapy
- Gastrointestinal Stromal Tumors (GISTs)
Background:
- Limited effective treatments existed for gastrointestinal stromal tumors (GISTs) previously.
- Systemic chemotherapy was ineffective for advanced GISTs.
- High recurrence rates were observed even after surgical resection for early-stage disease.
Purpose of the Study:
- To evaluate the efficacy of imatinib mesylate in treating gastrointestinal stromal tumors (GISTs).
- To assess the impact of imatinib on objective responses and overall survival in GIST patients.
- To review current and future therapeutic strategies for GIST management.
Main Methods:
- Clinical trials evaluating imatinib mesylate, a KIT inhibitor.
- Assessment of objective response rates and overall survival.
- Investigation of imatinib in neoadjuvant/adjuvant settings and other molecularly targeted agents for advanced disease.
Main Results:
- Imatinib mesylate demonstrated high efficacy in inducing objective responses in GIST patients.
- Imatinib significantly improved overall survival compared to previous treatment options.
- Ongoing studies are evaluating imatinib's role in locoregional disease and advanced GISTs.
Conclusions:
- Imatinib mesylate represents a highly effective therapeutic option for gastrointestinal stromal tumors (GISTs).
- Further research is needed to optimize imatinib dosage, duration, and resistance management.
- Novel molecularly targeted agents are under investigation for advanced GISTs.
